Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics

Česká verzia

Authors: M. Doubek ¹; A. Jungová ²; M. Brejcha ³; A. Panovská ¹; Y. Brychtová ¹; Z. Pospíšil ⁴; J. Mayer Za Českou Leukemickou Skupinu Pro Život (cell ¹; The Czech Leukemia Study Group For Life)
Authors place of work: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc. ¹; Hematologicko‑onkologické oddělení FN Plzeň, přednosta prim. MUDr. Vladimír Koza ²; Hematologické oddělení Onkologického centra J. G. Mendela Nový Jičín, přednosta prim. MUDr. Martin Brejcha ³; Ústav matematiky a statistiky Přírodovědecké fakulty MU Brno, ředitel prof. RNDr. Jiří Rosický, DrSc. ⁴
Published in the journal: Vnitř Lék 2009; 55(6): 549-554
Category: Original Contributions

Summary

Alemtuzumab is effective in B-cell chronic lymphocytic leukemia (CLL) with 17p deletion, which responds poorly to chemotherapeutic agents. Our retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced CLL, categorized by cytogenetic profile. Data were collected from 74 consecutive who had received alemtuzumab. Median of previous therapies was 2. The incidence of cytogenetic abnormalities was: trisomy 12, 10%; 13q deletion, 13%; 11q deletion 25%; 17p deletion, 26%; none of these, 26%. The overall response rate was 65% (11% complete remission, 54% partial remission) in the whole cohort. From start of alemtuzumab therapy, median progression‑free survival was 217 days, median time to alternative treatment was 287 days, and median overall survival was 999 days in the total cohort, respectively. Alemtuzumab was effective across all cytogenetic categories evaluated. There were no statistically significant differences between subgroups in the level of efficacy.

Key words:
alemtuzumab – chronic lymphocytic leukemia – cytogenetic risk – treatment

Zdroje

1. Doubek M, Ráčil Z, Mayer J. Klinické využití humanizované monoklonální protilátky alemtuzumab. 1. vyd. Brno: Masarykova univerzita 2006.

2. Dyer MJ. The role of CAMPATH-1H antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999; 26 (5 Suppl 14): S52–S57.

3. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137–143.

4. Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278–3281.

5. Stilgenbauer S, Döhner H. Campath-1H‑induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452–453.

6. Mayer J, Schwarz J, Doubek M et al. Co nám v každodenní praxi skutečně říkají tzv. moderní prognostické faktory u chronické lymfatické leukemie? Transf Hemat Dnes 2007; 13: 106–116.

7. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first‑line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616–5623.

8. Keating MJ, Coutré S, Rai K et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004; 4: 220–227.

9. Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

10. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.

11. Österborg A, Dyer MJS, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–1574.

12. Lundin J, Kimby E, Björkholm M et al. hase II trial of subcutaneous anti‑CD52monoclonal antibody alemtuzumab (Campath-1H) as first‑line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773.

13. Elter T, Borchmann P, Schulz H et al. Development of a new, four‑weekly schedule (FluCam) with concomitant aplication of Campath-1H and fludarabine in patients with relapsed/refractory CLL. Proc Am Soc Clin Oncol 2003; 22. Abstract 2331.

14. Montillo M, Tedeschi A, Rossi V et al. Alemtuzumab as consolidation after a response to fludarabine is effective to purge residual disease in patients with chronic lymphocytic leukemia. Blood 2004; 104. Abstract 479.

15. Moreton P, Kennedy B, Rawstron A et al. The correlation between the eradication of minimal residual disease (MRD) following alemtuzumab for CLL and overall survival. Proc Am Soc Clin Oncol 2004; 23. Abstract 6566.

16. Stilgenbauer S, Kröber A, Winkler D et al. Efficacy of subcutaneous alemtuzumab (Campath-1H) in genetic high‑risk, fludarabine-refractory CLL: CLL2H study of the German CLL Study Group (GCLLSG). Ann Oncol 2005; 43. Abstrakt 041.

17. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561.

18. Dickinson JD, Gilmore J, Iqbal J et al. 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. Leuk Lymphoma 2006; 47: 231–244.

19. Fiegl M, Falkner A, Hopfinger G et al. Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006; 107: 2408–2416.

20. Hui D, Lam W, Toze C et al. Alemtuzumab in clinical practice: a British Columbia experience. Leuk Lymphoma 2008; 49: 218–226.

21. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf.